Virtual screening is one of the most successful approaches for augmenting the drug discovery process. Currently, there is a notable shift towards machine learning (ML) methodologies to aid this process . Deep learning has recently gained considerable attention as it allows the model to "learn" to extract features that are relevant for the task at hand. We have developed a new deep neural network tailored to estimating the binding affinity of ligand-receptor complexes. The complex is represented with a 3D grid, and the model utilizes a 3D convolution to produce a feature map of this representation, treating the atoms of both proteins and ligands in the same manner. Our network was tested on the CASF "scoring power" benchmark and Astex diverse set and outperformed classical scoring functions. The model, together with usage instructions and examples, is available as a git repository at URL
Structure based ligand discovery is one of the most successful approaches for augmenting the drug discovery process. Currently, there is a notable shift towards machine learning (ML) methodologies to aid such procedures . Deep learning has recently gained considerable attention as it allows the model to "learn" to extract features that are relevant for the task at hand. We have developed a novel deep neural network estimating the binding affinity of ligand-receptor complexes. The complex is represented with a 3D grid, and the model utilizes a 3D convolution to produce a feature map of this representation, treating the atoms of both proteins and ligands in the same manner. Our network was tested on the CASF "scoring power" benchmark and Astex Diverse Set and outperformed classical scoring functions. The model, together with usage instructions and examples, is available as a git repository at URL
R
Virtual screening
Structure based ligand discovery
R
this process
such procedures
R
new
novel
D
tailored to
R
diverse set
Diverse Set